The DOI matches its OpenAlex record; 104 of the 104 references it cites were found in a registry or an index.
Targeted Therapies for Cancer 2004
Abstract
The regulatory agency approvals in the United States and Europe of imatinib mesylate (Gleevec) for patients with bcr/abl-positive chronic myelogenous leukemia, cetuximab (Erbitux) for patients with epidermal growth factor receptor overexpressing metastatic colorectal cancer, the antiangiogenesis agent bevacizumab (Avastin), and the proteasome inhibitor bortezomib (Velcade)--and the considerable public interest in new anticancer drugs that take advantage of specific genetic defects that render the malignant cells more likely to respond to specific treatment--are driving a new era of integrated diagnostics and therapeutics. The recent discovery of a drug response predicting activating mutation in the epidermal growth factor receptor gene for patients with non-small cell lung cancer treated with gefitinib (Iressa) has intensified this interest. In this review, the history of targeted anticancer therapies is highlighted, with focus on the development of molecular diagnostics for hematologic malignancies and the emergence of trastuzumab (Herceptin), an antibody-based targeted therapy for HER-2/neu overexpressing metastatic breast cancer: The potential of pharmacogenomic strategies and the use of high-density genomic microarrays to classify and select therapy for cancer are briefly considered. This review also considers the widely held view that, in the next 5 to 10 years, the clinical application of molecular diagnostics will further revolutionize the drug discovery and development process; customize the selection, dosing, route of administration of existing and new therapeutic agents; and truly personalize medical care for cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationVogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Weinshilboum, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020021 · Cited by 1,031
Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
Goldman, J. M., & Melo, J. V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020777 · Cited by 950
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Tamoxifen: a most unlikely pioneering medicine
Jordan, V. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1031 · Cited by 824
Soulieres, D., Senzer, N. N., Vokes, E. E., Hidalgo, M., Agarwala, S. S., & Siu, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.075 · Cited by 807
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Ross, J. S., Fletcher, J. A., Linette, G. P., Stec, J., Clark, E., Ayers, M., Symmans, W. F., Pusztai, L., & Bloom, K. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-307 · Cited by 610
Self-citationExpression of the prostate-specific membrane antigen.
Israeli, R., Powell, C. T., Corr, J., Fair, W. R., & Heston, W. D. W. (1994) · PubMed · Cited by 601
The EGFR as a target for anticancer therapy—focus on cetuximab
Baselga, J. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00233-7 · Cited by 563
Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A. K., Navarro, V., Knudsen, B., & Bander, N. H. (1997) · PubMed · Cited by 528
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
Shawver, L. K., Slamon, D., & Ullrich, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00039-9 · Cited by 522
Ross, J. S., Sheehan, C. E., Fisher, H. A. �., Kaufman, R. P., Kaur, P., Gray, K., Webb, I. J., Gray, G. S., Mosher, R. E., & Kallakury, B. (2003) · PubMed · Cited by 513
Self-citationA phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
COBLEIGH, M. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.013 · Cited by 488
The proteasome as a target for cancer therapy.
Voorhees, P. M., Dees, E. C., O’Neil, B. H., & Orlowski, R. Z. (2003) · PubMed · Cited by 455
Steroid hormone receptors in breast cancer management
Osborne, C. K. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006132427948 · Cited by 438
Jordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020449y · Cited by 414
Verweij, J., van Oosterom, A., Blay, J.-Y., Judson, I., Rodenhuis, S., van der Graaf, W., Radford, J., Le Cesne, A., Hogendoorn, P. C. W., di Paola, E. D., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00836-5 · Cited by 404
Jordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020450x · Cited by 396
Development of the Proteasome Inhibitor PS-341
Adams, J. (2002) · The Oncologist · doi:10.1634/theoncologist.7-1-9 · Cited by 369
Targeted therapy of cancer with radiolabeled antibodies.
Goldenberg, D. M. (2002) · PubMed · Cited by 318
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
Kelly, L. M., Yu, J.-C., Boulton, C. L., Apatira, M., Li, J., Sullivan, C. M., Williams, I., Amaral, S. M., Curley, D. P., Duclos, N., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00070-3 · Cited by 305
Buzdar, A. U., Robertson, J. F. R., Eiermann, W., & Nabholtz, J. (2002) · Cancer · doi:10.1002/cncr.10908 · Cited by 290
Trastuzumab: A Review of its Use in the Treatment of Metastatic Breast Cancer Overexpressing HER2
McKeage, K., & Perry, C. M. (2002) · Drugs · doi:10.2165/00003495-200262010-00008 · Cited by 289
Rosen, L. S. (2002) · Cancer Control · doi:10.1177/107327480200902s05 · Cited by 268
Wiseman, G. A., Gordon, L. I., Multani, P. S., Witzig, T. E., Spies, S., Bartlett, N. L., Schilder, R. J., Murray, J. L., Saleh, M., Allen, R. S., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4336 · Cited by 264
BANDER, N. H., TRABULSI, E. J., KOSTAKOGLU, L., YAO, D., VALLABHAJOSULA, S., SMITH-JONES, P., JOYCE, M. A., MILOWSKY, M., NANUS, D. M., & GOLDSMITH, S. J. (2003) · Journal of Urology · doi:10.1097/01.ju.0000091655.77601.0c · Cited by 263
de Jong, J. S., van Diest, P. J., van der Valk, P., & Baak, J. P. A. (1998) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199801)184:1<53::aid-path6>3.0.co;2-7 · Cited by 257
Herbst, R. S., & Langer, C. J. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31525 · Cited by 237
Mendel, D. B., Laird, A., Smolich, B. D., Blake, R., Liang, C., Hannah, A. L., Shaheen, R. M., Ellis, L. M., Weitman, S., Shawver, L. K., et al. (2000) · PubMed · Cited by 230
Antisense therapy in oncology: new hope for an old idea?
Tamm, I., Dörken, B., & Hartmann, G. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05629-x · Cited by 229
Larson, R., Boogaerts, M., Estey, E., Karanes, C., Stadtmauer, E., Sievers, E., Mineur, P., Bennett, J., Berger, M., Eten, C., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402677 · Cited by 221
Punt, C. J., Nagy, A., Douillard, J.-Y., Figer, A., Skovsgaard, T., Monson, J., Barone, C., Fountzilas, G., Riess, H., Moylan, E., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09836-7 · Cited by 213
Problems of Delivery of Monoclonal Antibodies: Pharmaceutical and Pharmacokinetic Solutions
Reilly, R. M., Sandhu, J., Alvarez-Diez, T. M., Gallinger, S., Kirsh, J., & Stern, H. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199528020-00004 · Cited by 187
Kuus-Reichel, K., Grauer, L. S., Karavodin, L. M., Knott, C., Krusemeier, M., & Kay, N. E. (1994) · Clinical Diagnostic Laboratory Immunology · doi:10.1128/cdli.1.4.365-372.1994 · Cited by 184
BANDER, N. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00358-0 · Cited by 162
Orlowski, R. Z., & Dees, E. C. (2002) · Breast Cancer Research · doi:10.1186/bcr460 · Cited by 150
Green, M. R. (2004) · New England Journal of Medicine · doi:10.1056/nejme048101 · Cited by 146
Clinical Use of Monoclonal Antibody HuJ591 Therapy: Targeting Prostate Specific Membrane Antigen
Nanus, D. M., Milowsky, M. I., Kostakoğlu, L., et al. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000095151.97404.7c · Cited by 145
Winter, G. P., & Harris, W. J. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90039-n · Cited by 127
Elliott, P. J., & Ross, J. S. (2001) · American Journal of Clinical Pathology · doi:10.1309/44hw-5ycj-fllp-3r56 · Cited by 125
Self-citationNewton, H. B. (2003) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.3.5.595 · Cited by 122
Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma
Dillman, R. O. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.126 · Cited by 115
Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia
Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00080-6 · Cited by 110
Pegram, M. D., & Reese, D. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70124-3 · Cited by 105
Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer
Hortobágyi, G. N. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90108-3 · Cited by 105
Self-citationCetuximab: In the Treatment of Metastatic Colorectal Cancer
Reynolds, N. A., & Wagstaff, A. J. (2004) · Drugs · doi:10.2165/00003495-200464010-00007 · Cited by 100
Imatinib alone and in combination for chronic myeloid leukemia
Druker, B. J. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)70042-0 · Cited by 100
Emerging Roles of Targeted Small Molecule Protein-Tyrosine Kinase Inhibitors in Cancer Therapy
Smith, J. K., Mamoon, N. M., & Duhé, R. J. (2003) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/000000003772462298 · Cited by 96
Antiangiogenesis drug promising for metastatic colorectal cancer
McCarthy, M. C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13603-3 · Cited by 94
Worland, P. J., Gray, K., Rolfe, P. M., Gray, K., & Ross, M. J. S. (2003) · American Journal of Clinical Pathology · doi:10.1309/y6lpc0lr726l9dx9 · Cited by 93
Anti‐tumor effects of toxins targeted to the prostate specific membrane antigen
Fracasso, G., Bellisola, G., Cingarlini, S., Castelletti, D., Prayer‐Galetti, T., Pagano, F. C., Tridente, G., & Colombatti, M. (2002) · The Prostate · doi:10.1002/pros.10117 · Cited by 92
Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer
Khalil, M. Y., Grandis, J. R., & Shin, D. M. (2003) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.3.3.367 · Cited by 92
Future of Monoclonal Antibodies in the Treatment of Hematologic Malignancies
Reff, M. E., Hariharan, K., & Braslawsky, G. R. (2002) · Cancer Control · doi:10.1177/107327480200900207 · Cited by 83
Treatment of Acute Promyelocytic Leukemia with ATRA and As2O3: A Model of Molecular
Fang, J., Chen, S., Tong, J., Wang, Z., & and, G.-Q. C. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.308 · Cited by 81
Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma
Schwartzberg, L. S. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00131-7 · Cited by 81
Current role of thalidomide in cancer treatment
Thomas, D. A., & Kantarjian, H. M. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200011000-00009 · Cited by 79
Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer
Nahta, R. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.016 · Cited by 77
Clinical issues in antibody design
Chester, K. A., & Hawkins, R. E. (1995) · Trends in biotechnology · doi:10.1016/s0167-7799(00)88968-4 · Cited by 75
Hormonal therapy of breast cancer
Locker, G. Y. (1998) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(98)90051-2 · Cited by 70
Gordon, L. I., Witzig, T. E., Wiseman, G., Flinn, I. W., Spies, S., Silverman, D. H. S., Emmanuolides, C., Cripe, L. D., Saleh, M. N., Czuczman, M. S., et al. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30148 · Cited by 70
Chen, H.-X., Gore‐Langton, R. E., & Cheson, B. D. (2001) · PubMed · Cited by 69
Campath-1H (Anti-CD52) Monoclonal Antibody Therapy in Lymphoproliferative Disorders
Pangalis, G. A., Dimopoulou, M., Angelopoulou, M. K., Tsekouras, C., Vassilakopoulos, T. P., Vaiopoulos, G., & Siakantaris, M. P. (2001) · Medical Oncology · doi:10.1385/mo:18:2:99 · Cited by 68
Pharmacogenomics — Teaching Old Drugs New Tricks
Weinstein, J. N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431910 · Cited by 65
Rituximab in the treatment of diffuse large B-cell lymphomas
Coiffier, B. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30153 · Cited by 63
Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries
Nielsen, U. B., & Marks, J. D. (2000) · Pharmaceutical Science & Technology Today · doi:10.1016/s1461-5347(00)00280-7 · Cited by 61
Reff, M. E., & Heard, C. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00132-9 · Cited by 61
Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer
Leonard, D. S., Hill, A. D. K., Kelly, L., Dijkstra, B., McDermott, E. W. M., & O’Higgins, N. J. (2002) · British journal of surgery · doi:10.1046/j.0007-1323.2001.02022.x · Cited by 54
Acute promyelocytic leukaemia: a review
Parmar, S., & Tallman, M. S. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.8.1379 · Cited by 52
A clinical and scientific overview of tositumomab and iodine I 131 tositumomab
Zelenetz, A. D. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70054-2 · Cited by 51
Introduction to Antibody Engineering and Phage Display
Watkins, N. A., & Ouwehand, W. H. (2000) · Vox Sanguinis · doi:10.1046/j.1423-0410.2000.7820072.x · Cited by 51
Evaluating Antiangiogenesis Agents in the Clinic
Sparano, J. A., Gray, R. J., Giantonio, B. J., O'Dwyer, P. J., & Comis, R. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0238 · Cited by 50
General aspects of anti-angiogenesis and cancer therapy
Zogakis, T. G., & Libutti, S. K. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.2.253 · Cited by 49
Commercial molecular diagnostics in the U.S.: The Human Genome Project to the clinical laboratory
Amos, J. A., & Patnaik, M. (2002) · Human Mutation · doi:10.1002/humu.10061 · Cited by 48
Monoclonal Antibody Therapy for Lymphoma
Dillman, R. O. (2001) · Cancer Practice · doi:10.1046/j.1523-5394.2001.009002071.x · Cited by 45
A clinical and scientific overview of tositumomab and iodine I 131 tositumomab
Zelenetz, A. D. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.23803 · Cited by 45
Technology evaluation: bevacizumab, Genentech/Roche.
Salgaller, M. L. (2003) · PubMed · Cited by 42
Inhibition of Tumor Angiogenesis by Angiostatin: From Recombinant Protein to Gene Therapy
Dell’Eva, R., Pfeffer, U., Indraccolo, S., Albini, A., & Noonan, D. M. (2002) · Endothelium · doi:10.1080/10623320210712 · Cited by 41
Monoclonal Antibody-Based Therapy Strategies: Providing Options for the Cancer Patient
Milenic, D. E. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023393963 · Cited by 38
Steroid hormone receptors in breast cancer management
Osborne, C. K. (1998) · Springer eBooks · doi:10.1007/978-1-4615-5195-9_4 · Cited by 36
Transcriptional profiling in cancer: the path to clinical pharmacogenomics
Slonim, D. K. (2001) · Pharmacogenomics · doi:10.1517/14622416.2.2.123 · Cited by 35
Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy
Lara, P. N., Davies, A. M., Mack, P. C., Mortenson, M. M., Bold, R. J., Gumerlock, P. H., & Gandara, D. R. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.12.013 · Cited by 34
Isaacs, J. D. (2001) · Lara D. Veeken · doi:10.1093/rheumatology/40.7.724 · Cited by 33
Early Phase I/II Trials with Gemtuzumab Ozogamicin (Mylotarg®) in Acute Myeloid Leukemia
Nabhan, C., & Tallman, M. S. (2002) · Clinical Lymphoma · doi:10.3816/clm.2002.s.004 · Cited by 31
CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond
Dumont, F. J. (2002) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2.1.23 · Cited by 31
Antibody-directed therapies for hematological malignancies
Linenberger, M. L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02278-5 · Cited by 30
Anti-tumor Effects of Letrozole
Miller, W. R., Anderson, T. J., & Dixon, J. M. (2002) · Cancer Investigation · doi:10.1081/cnv-120014882 · Cited by 30
Lemonick, M. D., & Park, A. (2001) · PubMed · Cited by 29
Cetuximab for treatment of metastatic colorectal cancer
Cerea, G., Ricotta, R., Schiavetto, I., Maugeri, M. R., Bianchi, A. S., Moroni, M., Artale, S. A., & Siena, S. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl954 · Cited by 24
The evolving role of specific estrogen receptor modulators (SERMs)
Ibrahim, N. K., & Hortobágyi, G. N. (1999) · Surgical Oncology · doi:10.1016/s0960-7404(99)00047-x · Cited by 23
Self-citationHORMONAL THERAPY FOR BREAST CANCER
Gradishar, W. J., & Jordan, V. C. (1999) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70064-2 · Cited by 23
Stadtmauer, E. A. (2002) · Clinical Lymphoma · doi:10.3816/clm.2002.s.005 · Cited by 18
Engineered Antibody for Treating Lymphoma
Stevenson, G. T., Anderson, V. A., & Leong, W. S. (2002) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-56352-2_13 · Cited by 17
Regulators of apoptosis as anticancer targets
Tolcher, A. W. (2002) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(02)00046-1 · Cited by 17
Gastrointestinal Stromal Tumors: A Paradigm for Molecularly Targeted Therapy
von Mehren, M. (2003) · Cancer Investigation · doi:10.1081/cnv-120022374 · Cited by 14
Cited by
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Ge, Z., & Liu, S. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60048c · Cited by 914
Castano, A. P., Demidova, T. N., & Hamblin, M. R. (2005) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/s1572-1000(05)00030-x · Cited by 767
Application of Nanotechnology in Cancer Therapy and Imaging
Wang, X., Yang, L., Chen, Z., & Shin, D. M. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0003 · Cited by 700
Genomic and personalized medicine: foundations and applications
Ginsburg, G. S., & Willard, H. F. (2009) · Translational Research · doi:10.1016/j.trsl.2009.09.005 · Cited by 637
Self-citation
Metadata
- Authors
- Ross, J. S., Schenkein, D. P., Pietrusko, R. G., Rolfe, M., Linette, G. P., Stec, J. J., Stagliano, N. E., Ginsburg, G. S., Symmans, W. F., Pusztai, L., & Hortobágyi, G. N.
- Venue
- American Journal of Clinical Pathology
- Publisher
- Oxford University Press
- Published
- 2004-01-01
- Volume
- 122
- Issue
- 4
- Pages
- 598-609
- ISSN
- 0002-9173 (ISSN-L)
- OpenAlex
- W2170083676
- Cited by
- 286
- References
- 104
- FWCI
- 26.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.